Top Page
Memphasys Ltd
(Sydney:MEM)
Memphasys Ltd (MEM) vs. iShares MSCI Australia ETF (EWA)
Memphasys Ltd Business Overview & Revenue Model
Memphasys Ltd Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 349.34K | 60.00K | 15.37K | 27.15K | 211.48K | 0.00 | Gross Profit |
| -316.83K | -1.57M | -824.86K | -922.60K | -48.00K | -196.23K | EBIT |
| -3.88M | -5.24M | -3.63M | -2.71M | -1.69M | -1.26M | EBITDA |
| -3.06M | -3.31M | -2.36M | -1.39M | -1.14M | -869.05K | Net Income Common Stockholders |
| -5.11M | -4.44M | -3.40M | -2.08M | -1.49M | -1.13M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 516.27K | 277.80K | 680.58K | 311.83K | 2.05M | 2.01M | Total Assets |
| 10.99M | 12.43M | 14.67M | 14.12M | 14.58M | 11.30M | Total Debt |
| 4.30M | 4.81M | 6.37M | 5.56M | 5.36M | 1.04M | Net Debt |
| 3.78M | 4.53M | 5.69M | 5.25M | 3.31M | -969.65K | Total Liabilities |
| 4.91M | 5.59M | 7.28M | 6.47M | 5.97M | 1.54M | Stockholders Equity |
| 6.07M | 6.84M | 7.38M | 7.65M | 8.61M | 9.76M |
| Cash Flow | Free Cash Flow | ||||
| -3.12M | -3.87M | -3.23M | -2.61M | -2.96M | -3.02M | Operating Cash Flow |
| -3.27M | -3.23M | -1.41M | 311.82K | 47.25K | 120.19K | Investing Cash Flow |
| -274.88K | -711.05K | -1.98M | -3.08M | -3.00M | -3.14M | Financing Cash Flow |
| 4.03M | 3.54M | 3.75M | 1.03M | 2.99M | 4.11M |
Memphasys Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
37 Underperform | AU$7.93M | ― | -80.47% | ― | -41.19% | 20.93% | |
| $141.37M | 19.53 | 17.87% | ― | ― | ― | ||
| $12.54M | ― | -130.18% | ― | ― | ― | ||
61 Neutral | AU$19.76M | 140.00 | -3.11% | ― | 89.13% | 69.57% |
Memphasys Ltd Corporate Events
Memphasys Limited has announced a change in its external auditors, appointing BDO Audit Pty Ltd following the resignation of Pitcher Partners. This decision comes as part of a corporate review by the Board, aligning with the company’s strategic move towards the international commercialization of its Felix™ Device.
Memphasys Ltd has completed a placement of 212,583,334 ordinary shares at $0.006 per share without disclosure under Part 6D.2 of the Corporations Act. The company has ensured compliance with relevant provisions of the Corporations Act, indicating transparency and adherence to regulatory standards, which may bolster investor confidence.
Memphasys Ltd announced the application for quotation of 212,583,334 ordinary fully paid securities on the ASX, issued as part of a previously announced transaction. This move is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its industry positioning and offering new opportunities for stakeholders.
Memphasys Ltd has announced an update regarding the proposed issue of securities, with changes to the issue date and option expiry date now set for April 15, 2025, and April 15, 2027, respectively. This update reflects the company’s strategic financial maneuvers to leverage its ASX Listing Rule 7.1 capacity, potentially impacting its market positioning and providing stakeholders with revised timelines for investment opportunities.
Memphasys Limited has secured A$1.275 million through a strategic placement to advance the commercialisation of its Felix™ and RoXsta™ systems. The funds will support licensing, joint ventures, and distribution agreements, particularly following successful clinical trial results for the Felix™ System, which demonstrated superior performance to existing sperm preparation methods. The RoXsta™ System is gaining traction in veterinary applications, showing potential for livestock reproductive health and early mastitis detection in dairy cattle.
Memphasys Ltd has announced a proposed issue of 212,500,000 new securities, which will be fully paid ordinary shares. This move is part of a placement or other type of issue, with the proposed issue date set for April 11, 2025. This announcement could potentially impact the company’s market positioning by increasing its capital base, which may be used for further business development or operational expansion.
Memphasys Limited announced the successful completion of a pilot study using its RoXsta™ antioxidant assay system in heifers, which demonstrated the system’s ability to reliably measure antioxidant capacity, though it did not find a significant link between antioxidant levels and pregnancy outcomes. The study highlighted the potential for RoXsta™ in cattle reproduction, particularly in bulls, and identified its promising application in early detection of mastitis in dairy cattle. A larger study with 120 bulls, funded by a multinational veterinary pharmaceutical partner, is planned to further explore these applications, indicating a strong industry interest in the technology.
Memphasys Limited announced successful results from a pivotal clinical trial for its Felix™ System, confirming its superior performance in sperm selection for ART. The trial demonstrated the system’s efficiency, safety, and preference among laboratory staff over traditional methods, paving the way for regulatory submissions and commercial expansion in multiple global markets. With existing distribution agreements and strategic partnerships, Memphasys is well-positioned to accelerate sales and further commercialize the Felix™ System, reinforcing its status as a leading innovator in sperm separation technology.
Memphasys Limited has requested a trading halt on its securities pending an announcement regarding the results of its 2-year Felix™ System clinical trial. The trading halt is intended to ensure an orderly market, and the company expects to release the announcement before the commencement of trading on March 24, 2025.
Memphasys Limited has secured a $472,236 loan against its 2024/25 R&D Tax Rebate to support the commercial activities of its FelixTM System following the completion of clinical trials and CE Mark registration. The loan, which carries a 15% annual interest rate and is repayable from the expected $900k R&D Tax Rebate in September 2025, will also aid in managing the company’s working capital requirements, reflecting Memphasys’ strategic approach to funding its development portfolio.